Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers

  • Diesch, Jeannine|||0000-0002-4667-3468
  • Zwick, Anabel
  • Garz, Anne-Kathrin
  • Palau de Miguel, Anna|||0000-0003-2131-1265
  • Buschbeck, Marcus|||0000-0002-3218-4567
  • Götze, Katharina S.|||0000-0002-6276-8002
The azanucleosides azacitidine and decitabine are currently used for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible for intensive chemotherapy but are also being explored in other hematologic and solid cancers. Based on their capacity to interfere with the DNA methylation machinery, these drugs are also referred to as hypomethylating agents (HMAs). As DNA methylation contributes to epigenetic regulation, azanucleosides are further considered to be among the first true "epigenetic drugs" that have reached clinical application. However, intriguing new evidence suggests that DNA hypomethylation is not the only mechanism of action for these drugs. This review summarizes the experience from more than 10 years of clinical practice with azanucleosides and discusses their molecular actions, including several not related to DNA methylation. A particular focus is placed on possible causes of primary and acquired resistances to azanucleoside treatment. We highlight current limitations for the success and durability of azanucleoside-based therapy and illustrate that a better understanding of the molecular determinants of drug response holds great potential to overcome resistance.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MacroH2A1.1 regulates mitochondrial respiration by limiting nuclear NAD + consumption

  • Posavec Marjanović, Melanija
  • Hurtado-Bagès, Sarah|||0000-0002-6588-0876
  • Lassi, Maximilian
  • Valero, Vanesa
  • Malinverni, Roberto|||0000-0002-0113-3417
  • Delage, Hélène
  • Navarro, Miriam
  • Corujo, David|||0000-0001-7930-0935
  • Guberovic, Iva
  • Douet, Julien
  • Gama-Pérez, Pau
  • Garcia-Roves, Pablo M.|||0000-0001-9826-1740
  • Ahel, Ivan
  • Ladurner, Andreas G.|||0000-0003-3835-232X
  • Yanes, Oscar|||0000-0003-3695-7157
  • Bouvet, Philippe|||0000-0003-4524-2233
  • Suelves Esteban, Mònica|||0000-0001-7095-5804
  • Teperino, Raffaele
  • Pospisilik, J. Andrew
  • Buschbeck, Marcus|||0000-0002-3218-4567
Histone variants are structural components of eukaryotic chromatin that can replace replication-coupled histones in the nucleosome. The histone variant macroH2A.1.1 contains a macrodomain able to bind NAD + derived metabolites. Here, we report that macroH2A.1.1 is rapidly induced during myogenic differentiation through a switch in alternative splicing. Importantly, myotubes lacking macroH2A.1.1 display a defect in mitochondrial respiratory capacity. We find that the metabolite-interacting macrodomain is essential for sustaining optimal mitochondrial function, but dispensable for gene regulation. Through direct binding, macroH2A.1.1 inhibits basal poly-ADP ribose polymerase 1 activity and thus reduces nuclear NAD+ consumption. Consequentially, accumulation of the NAD + precursor NMN allows the maintenance of mitochondrial NAD + pools critical for respiration. Our data indicate that macroH2A.1.1-containing chromatin regulates mitochondrial respiration by limiting nuclear NAD+ consumption and establishing a buffer of NAD + precursors in differentiated cells.